Cerep Grants BioPrint® Access to AstraZeneca
News May 12, 2006
Through this alliance, AstraZeneca will have non-exclusive access to physicochemical, pharmacological and clinical data on BioPrint® compounds as well as to BioPrint® informatics tools to support internal drug discovery and development.
Payment of the license fee has been recognized upon acceptance of the data and IT tools delivered by Cerep in the first quarter 2006.
"We are very happy to announce this alliance with AstraZeneca," commented Mark Crawford, Executive Vice President for Cerep.
"BioPrint® has been established in the industry as an extremely useful tool to support drug discovery and drug development."
"We are particularly proud to have the value of BioPrint® recognized by AstraZeneca."
"We believe that database-supported pharmaco-informatics can play an important role in expediting drug discovery. We have been pleased with Cerep's BioPrint® database and we look forward to implementing this tool at AstraZeneca," commented Tim Hammond, Vice President of Safety Assessment UK, for AstraZeneca.
Modified Form of Botox Could Replace Opioids as Treatment for Chronic PainNews
A modified form of botulinum toxin gives long-lasting pain relief in mice without adverse effects and, in time, could replace opioid drugs as a safe and effective way of treating chronic pain, according to new research.READ MORE
Key Ingredient in Diabetes Drug Modified to Improve Side EffectsNews
Improved medications for Type 2 diabetes are one step closer thanks to a new discovery reported this week. By modifying the key ingredient in current diabetes drugs, the researchers produced a compound that was effective for hyperglycemia in animal trials, yet without the most problematic side effects of current drugs.READ MORE
Tackling Cancer at Ground Zero: Designer Molecule Inhibits Protein TargetNews
A new molecule designed by University of Adelaide researchers shows great promise for future treatment of many cancers. The new molecule successfully targets a protein that plays a major role in the growth of most cancers.READ MORE